Kastus

Kastus, also known as Kastus Technologies, is an Irish nanotechnology company headquartered in Dublin. It develops surface treatments intended to reduce the persistence and transmission of microorganisms on commonly touched or used materials. Its work has focused particularly on antimicrobial and antiviral coatings for indoor surfaces, ceramic tiles, glass, and electronic touchscreens. The company was founded in Dublin in 2014 by John Browne after approximately a decade of collaborative research with Dublin Institute of Technology. Its founding rationale was linked to the growing public-health concern surrounding antibiotic-resistant infections and the role that indoor surfaces can play in the persistence and transfer of pathogens. Rather than relying solely on cleaning regimes, Kastus has pursued technologies that can be incorporated into or applied to manufactured surfaces so that antimicrobial properties remain present during ordinary use. A significant stage in the company’s early development came through research associated with Sligo Institute of Technology. In April 2016, the institute announced the creation of a non-toxic antimicrobial nanotechnology supported by Kastus. The research was backed by a reported €1.5 million investment from Atlantic Bridge, providing a basis for further development and commercialization. Kastus subsequently positioned the technology for use across multiple industrial sectors rather than limiting it to a single finished product category. In 2017, the company’s work coincided with increased governmental attention to antimicrobial resistance in Ireland. The Department of Health’s National Action Plan on Antimicrobial Resistance 2017–2020 identified antimicrobial resistance as a major threat and emphasized the need for new approaches. Kastus received several Irish innovation and impact recognitions that year, including the Spin-out Company Impact Award, Irish Times Innovation of the Year, Irish Times Life Sciences and Healthcare recognition, and a KTI Impact Award. Kastus expanded into commercially manufactured surfaces in 2018 through a partnership with Al Maha Ceramics, an Oman-based ceramic-tile producer exporting to markets in Asia and Africa. The collaboration produced the iProtect range of antimicrobial tiles, giving Kastus a route to embed its technology into architectural and interior-surface products. This partnership illustrated the company’s business model of licensing, technology integration, and collaboration with established manufacturers. During 2020, Kastus extended its research and commercial focus to antiviral protection for touchscreens and other high-contact electronic surfaces. The company described applications intended to address the spread of infectious diseases, including concerns intensified by the COVID-19 pandemic. It received European Union funding to develop and broaden these technologies and formed partnerships with companies including Lenovo. Kastus’s work in this area placed it at the intersection of nanotechnology, electronics, infection control, and materials engineering. In 2021, Kastus raised €5.65 million in a Series A financing round. The stated purpose was to expand its global commercial team and respond to demand for antiviral surface-protection technology. The financing indicated a shift from primarily research-led development toward international commercialization. Kastus has also appeared in technology, life-sciences, medical-technology, and entrepreneurship award programs, including as a 2020 Med Tech Award finalist and an EY Entrepreneur Of The Year finalist. Kastus’s positioning is based on applying nanotechnology to manufactured surfaces in order to provide durable, non-toxic antimicrobial or antiviral functionality. Its potential customer base includes materials manufacturers, electronics companies, construction and interior-product suppliers, healthcare-related organizations, and other businesses seeking surface-based infection-control solutions. The available reference material does not establish a complete current product portfolio, ownership structure, leadership roster, website, or present geographic revenue distribution.

Kastus Technologies emerged from a long-running research collaboration involving John Browne and Dublin Institute of Technology. After around ten years of collaborative work, Browne founded Kastus in Dublin in 2014. The company was established against a backdrop of increasing concern about antimicrobial resistance and the ability of pathogens to persist on indoor and frequently touched surfaces. The early research program sought to create a non-toxic antimicrobial nanotechnology that could be incorporated into commercial materials. In April 2016, Sligo Institute of Technology announced the creation of such a technology with Kastus support. The development was associated with €1.5 million in funding from Atlantic Bridge and was intended to support global commercialization. Kastus’s approach was to work with manufacturers so that antimicrobial characteristics could be integrated into finished products rather than offered only as a standalone cleaning or disinfection service. Irish public-health policy gave the company’s mission additional relevance. In October 2017, Ireland’s Department of Health published the National Action Plan on Antimicrobial Resistance 2017–2020. The plan highlighted antimicrobial resistance as a serious and urgent threat, reinforcing the broader context in which Kastus was developing surface-based technologies. Kastus received several awards and industry recognitions in 2017, including the Spin-out Company Impact Award, Irish Times Innovation of the Year, Irish Times Life Sciences and Healthcare recognition, and a KTI Impact Award. The company’s first clearly identified commercial product collaboration came in 2018, when it partnered with Al Maha Ceramics, an Oman-based ceramic-tile manufacturer. Al Maha exported to 15 countries in Asia and Africa, and the partnership used Kastus technology in a new tile range called iProtect. This move connected Kastus’s nanotechnology with construction, interiors, and architectural materials, while giving the company access to an established manufacturing and distribution network. In 2020, Kastus broadened its technology work to antiviral applications for touchscreens and other high-contact electronic surfaces. The COVID-19 pandemic increased attention on shared touch interfaces and the potential role of persistent surface protection. Kastus received European Union funding for further development and expansion of these applications and reported partnerships with companies including Lenovo. The same period brought recognition in medical technology and entrepreneurship circles, including finalist status for a Med Tech Award and for EY Entrepreneur Of The Year. Kastus raised €5.65 million in a Series A round in 2021. The financing was intended to build the company’s global commercial team and meet growing demand for antiviral surface-protection technology. This represented an important transition from laboratory and institutional research toward broader commercial deployment. The company’s stated or described applications have included ceramics, glass, touchscreens, and other manufactured surfaces where antimicrobial or antiviral performance may be valuable. The available material identifies Kastus as an active Irish nanotechnology company but does not provide a complete account of its later corporate structure, current executives, ownership, website, product sales, or financial performance. Its documented history is therefore best understood as the development of a university-linked materials technology into a manufacturer-partnership and licensing-oriented business with international ambitions.

• 2021

  Series A financing

  [1]Kastusen.wikipedia.org

  Kastus raised €5.65 million in Series A funding to expand its global commercial team and support commercialization of antiviral surface-protection technology.

• 2020

  Expansion into antiviral touchscreen technology

  [1]Kastusen.wikipedia.org

  Kastus developed antimicrobial and antiviral technologies for touchscreens and related high-contact surfaces, supported by European Union funding and partnerships including Lenovo.

• 2018

  iProtect ceramic-tile partnership

  [1]Kastusen.wikipedia.org

  Kastus partnered with Al Maha Ceramics to apply its antimicrobial technology to the iProtect ceramic-tile range.

• 2017

  Recognition in Irish innovation and impact awards

  [1]Kastusen.wikipedia.org

  Kastus received or was associated with several 2017 recognitions, including the Spin-out Company Impact Award, Irish Times innovation and life-sciences awards, and a KTI Impact Award.

• 2016

  Non-toxic antimicrobial nanotechnology announced

  [1]Kastusen.wikipedia.org

  Sligo Institute of Technology announced antimicrobial nanotechnology developed with Kastus support, backed by reported Atlantic Bridge funding of €1.5 million.

• 2014

  Kastus founded in Dublin

  [1]Kastusen.wikipedia.org

  John Browne founded Kastus after approximately a decade of collaborative research with Dublin Institute of Technology.

A research-driven Irish nanotechnology company focused on embedding non-toxic antimicrobial and antiviral properties into manufactured surfaces, with applications spanning ceramic tiles, glass, electronic touchscreens, and other high-contact materials.

• Antimicrobial ceramic tiles · 2018

  iProtect

  iProtect is a range of ceramic tiles developed through Kastus’s partnership with Al Maha Ceramics. The range incorporates Kastus antimicrobial technology into a manufactured tile product intended for interior and architectural surfaces. Al Maha Ceramics exported to markets in Asia and Africa, providing the collaboration with an international route to market. The available reference material does not specify the complete tile catalog, technical performance claims, or current availability.

• Surface-treatment technology · 2016

  Kastus antimicrobial nanotechnology

  Kastus’s core technology is described as a non-toxic antimicrobial nanotechnology designed to provide persistent protection on or within manufactured surfaces. It was developed through research connected with Dublin Institute of Technology and Sligo Institute of Technology and has been positioned for use across multiple material categories. The available sources do not disclose the formulation, manufacturing process, or full range of licensing arrangements.

• Antiviral electronic-surface protection · 2020

  Kastus antiviral touchscreen technology

  This technology applies Kastus’s surface-protection approach to touchscreens and other frequently touched electronic interfaces. It was developed and expanded during 2020, when concern about surface transmission of infectious disease increased, and was supported by European Union funding. Kastus also reported partnerships with companies including Lenovo. Specific device models, deployment volumes, and present commercial availability are not established in the supplied material.

• 2021

  Series A financing for global commercializationStrategy

  Background

  Kastus reported growing demand for antiviral surface-protection technology and required additional commercial capacity to pursue international opportunities.

  Action taken

  The company raised €5.65 million in Series A funding and planned to use the capital to build out its global commercial team.

  Aftermath

  The financing supported Kastus’s transition toward broader international commercialization, although subsequent operating results are not stated in the available material.

  Series A financing. €5.65 million raised (2021)

  Source

• 2020

  Expansion from antimicrobial materials into antiviral touch surfacesStrategy

  Background

  The COVID-19 period increased attention on shared touchscreens and the possible role of surface technologies in reducing the persistence or transfer of infectious agents.

  Action taken

  Kastus developed antiviral and antimicrobial technology for touchscreens, sought European Union development funding, and pursued partnerships including Lenovo.

  Aftermath

  The move broadened Kastus’s addressable market from architectural and interior materials toward electronics and high-contact interfaces. The supplied sources do not quantify commercial adoption.

  Source

• 2018

  Commercial introduction of iProtect tilesProduct launch

  Background

  Kastus needed a commercial manufacturing route for its antimicrobial surface technology, while Al Maha Ceramics had an established ceramic-tile business and export reach across Asia and Africa.

  Action taken

  Kastus partnered with Al Maha Ceramics to incorporate its antimicrobial technology into the iProtect ceramic-tile range.

  Aftermath

  The partnership extended Kastus’s technology from research and development into architectural and interior-surface products. Detailed sales results and the current status of the range are not provided.

  Source

• 2020-05-26

  ZetaDisplay launches technology partnership with Kastus[2]ZetaDisplay与Kastus推出技术合作finanznachrichten.de

  Reported: 2020-05-26

  ZetaDisplay announced a technology partnership with Kastus, whose antimicrobial surface-coating technology is intended for integration into ZetaDisplay's product portfolio and can be applied to touchscreens and displays.

1. 1Kastusen.wikipedia.org
2. 2ZetaDisplay与Kastus推出技术合作finanznachrichten.de